Article Data

  • Views 1272
  • Dowloads 207

Review

Open Access

Sexual function and fertility preservation in testicular cancer survivors

  • Shane Davis1
  • Labeeqa Khizir1
  • Benjamin Lichtbroun1
  • Thomas Jang1
  • Saum Ghodoussipour1,*,
  • Danielle Velez1

1Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA

DOI: 10.22514/jomh.2023.011 Vol.19,Issue 2,February 2023 pp.1-8

Submitted: 29 September 2022 Accepted: 17 January 2023

Published: 28 February 2023

*Corresponding Author(s): Saum Ghodoussipour E-mail: sg1621@cinj.rutgers.edu

Abstract

Testicular cancer is a common cancer among reproductive age men, with the necessary treatment options having varying impacts on fertility and sexual function. Treatment begins with orchiectomy and is often followed by a combination of chemotherapy, radiation, and/or retroperitoneal lymph node dissection, which have different effects on spermatogenesis, gonadotropin levels, and ejaculation. Alkylating agents such as cisplatin are commonly used for testicular cancer and are amongst the most spermatotoxic chemotherapeutic agents. Radiation poses gonadotoxic effects despite gonadal shielding due to a scatter effect. Suprahilar and bilateral retroperitoneal lymph node dissections can cause ejaculatory dysfunction. Options to preserve fertility vary by pubertal status. While the standard recommendation for post pubertal patients is cryopreservation, prepubertal patients rely on experimental protocols for cryopreservation of germ cells with stem cell capabilities, with the hope that these cells will one day be stimulated to produce sperm. These topics are reviewed to give insight into current literature around fertility in testicular cancer survivorship and determine best possible practices in fertility preservation among patients.


Keywords

Testicular cancer; Fertility; Cryopreservation; Fertility preservation; Sexual function; Survivorship


Cite and Share

Shane Davis,Labeeqa Khizir,Benjamin Lichtbroun,Thomas Jang,Saum Ghodoussipour,Danielle Velez. Sexual function and fertility preservation in testicular cancer survivors. Journal of Men's Health. 2023. 19(2);1-8.

References

[1] Society A. Cancer treatment & survivorship facts & figures 2019–2021. American Cancer Society Atlanta. 2019.

[2] Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. British Journal of Cancer. 2005; 93: 200–207.

[3] Surveillance, Epidemiology and End Results (SEER) Program. 2015. Available at: www.seer.cancer.gov (Accessed: 09 October 2022)

[4] Hanna N, Einhorn LH. Testicular cancer: a reflection on 50 years of discovery. Journal of Clinical Oncology. 2014; 32: 3085–3092.

[5] Carrière P, Baade P, Fritschi L. Population based incidence and age distribution of spermatocytic seminoma. Journal of Urology. 2007; 178: 125–128.

[6] Brodsky MS. Testicular cancer survivors’ impressions of the impact of the disease on their lives. Qualitative Health Research. 1995; 5: 78–96.

[7] Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. Journal of Clinical Oncology. 2002; 20: 1880–1889.

[8] Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Oncologists’ attitudes and practices regarding banking sperm before cancer treatment. Journal of Clinical Oncology. 2002; 20: 1890–1897.

[9] Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. Journal of Clinical Oncology. 2018; 36: 1994–2001.

[10] Wiechno P, Demkow T, Kubiak K, Sadowska M, Kamińska J. The quality of life and hormonal disturbances in testicular cancer survivors in cisplatin era. European Urology. 2007; 52: 1448–1455.

[11] Rossen P, Pedersen AF, Zachariae R, von der Maase H. Sexuality and body image in long-term survivors of testicular cancer. European Journal of Cancer. 2012; 48: 571–578.

[12] Kim C, McGlynn KA, McCorkle R, Li Y, Erickson RL, Ma S, et al. Sexual functioning among testicular cancer survivors: a case-control study in the U.S. Journal of Psychosomatic Research. 2012; 73: 68–73.

[13] La Vignera S, Cannarella R, Duca Y, Barbagallo F, Burgio G, Compagnone M, et al. Hypogonadism and sexual dysfunction in testicular tumor survivors: a systematic review. Frontiers in Endocrinology. 2019; 10: 264.

[14] Jonker-Pool G, Basten JPV, Hoekstra HJ, Driel MFV, Sleijfer DT, Koops HS, et al. Sexual functioning after treatment for testicular cancer. Cancer. 1997; 80: 454–464.

[15] Rosendal S, Kristensen E, Giraldi A. Sexual dysfunctions in men treated for testicular cancer—secondary publication. Danish Medical Bulletin. 2008; 55: 211–215.

[16] Arai Y, Kawakita M, Okada Y, Yoshida O. Sexuality and fertility in long-term survivors of testicular cancer. Journal of Clinical Oncology. 1997; 15: 1444–1448.

[17] Lange PH, Narayan P, Vogelzang NJ, Shafer RB, Kennedy BJ, Fraley EE. Return of fertility after treatment for nonseminomatous testicular cancer: changing concepts. Journal of Urology. 1983; 129: 1131–1135.

[18] Bancroft J, Graham CA, Janssen E, Sanders SA. The dual control model: current status and future directions. Journal of Sex Research. 2009; 46: 121–142.

[19] Rastrelli G, Corona G, Maggi M. Testosterone and sexual function in men. Maturitas. 2018; 112: 46-52.

[20] Leitner SP, Bosl GJ, Bajorunas D. Gonadal dysfunction in patients treated for metastatic germ-cell tumors. Journal of Clinical Oncology. 1986; 4: 1500–1505.

[21] Bolen D, Burkhard FC, Mills R, Sonntag RW, Studer UE. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. Journal of Urology. 2001; 165: 441–444.

[22] Rieker PP, Edbril SD, Garnick MB. Curative testis cancer therapy: psychosocial sequelae. Journal of Clinical Oncology. 1985; 3: 1117–1126.

[23] Schover LR, von Eschenbach AC. Sexual and marital relationships after treatment for nonseminomatous testicular cancer. Urology. 1985; 25: 251–255.

[24] Schover LR, Gonzales M, von Eschenbach AC. Sexual and marital relationships after radiotherapy for seminoma. Urology. 1986; 27: 117–123.

[25] Gritz ER, Wellisch DK, Siau J, Wang H. Long-term effects of testicular cancer on marital relationships. Psychosomatics. 1990; 31: 301–312.

[26] Sheppard C, Wylie KR. An assessment of sexual difficulties in men after treatment for testicular cancer. Sexual and Relationship Therapy. 2001; 16: 47–58.

[27] Tinkler SD, Howard GCW, Kerr GR. Sexual morbidity following radiotherapy for germ cell tumours of the testis. Radiotherapy and Oncology. 1992; 25: 207–212.

[28] Chapple A, McPherson A. The decision to have a prosthesis: a qualitative study of men with testicular cancer. Psycho-Oncology. 2004; 13: 654–664.

[29] Carpentier MY, Fortenberry JD. Romantic and sexual relationships, body image, and fertility in adolescent and young adult testicular cancer survivors: a review of the literature. Journal of Adolescent Health. 2010; 47: 115–125.

[30] Loh-Doyle J, Ghodoussipour S, Daneshmand S. 105 factors associated with testicular prostheses availability and implantation. The Journal of Sexual Medicine. 2017; 14: e38–e39.

[31] Hassan HC, Cullen IM, Casey RG, Rogers E. Gynaecomastia: an endocrine manifestation of testicular cancer. Andrologia. 2008; 40: 152–157.

[32] Heidenreich A, Weissbach L, Höltl W, Albers P, Kliesch S, Köhrmann KU, et al. Organ sparing surgery for malignant germ cell tumor of the testis. The Journal of Urology. 2001; 29: 2161–2165.

[33] Shukla AR, Woodard C, Carr MC, Huff DS, Canning DA, Zderic SA, et al. Experience with testis sparing surgery for testicular teratoma. Journal of Urology. 2004; 171: 161–163.

[34] Jacobsen KD, Theodorsen L, Fossa SD. Spermatogenesis after unilateral orchiectomy for testicular cancer in patients following surveillance policy. Journal of Urology. 2001; 165: 93–96.

[35] Petersen PM, Skakkebaek NE, Rorth M, Giwercman A. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. Journal of Urology. 1999; 161: 822–826.

[36] Vakalopoulos I, Dimou P, Anagnostou I, Zeginiadou T. Impact of cancer and cancer treatment on male fertility. Hormones. 2015; 14: 579–589.

[37] Fosså SD, Aabyholm T, Vespestad S, Norman N, Ous S. Semen quality after treatment for testicular cancer. European Urology. 1993; 23: 172–176.

[38] Fosså SD, Theodorsen L, Norman N, Aabyholm T. Recovery of impaired pretreatment spermatogenesis in testicular cancer. Fertility and Sterility. 1990; 54: 493–496.

[39] Moody JA, Ahmed K, Yap T, Minhas S, Shabbir M. Fertility managment in testicular cancer: the need to establish a standardized and evidence-based patient-centric pathway. BJU International. 2019; 123: 160–172.

[40] Fosså SD, Abyholm T, Aakvaag A. Spermatogenesis and hormonal status after orchiectomy for cancer and before supplementary treatment. European Urology. 1984; 10: 173–177.

[41] Hartlapp J, Brensing K, Voss K, Deitenbeck R, Mumperow E. Long-term impairments of the gonadal function after cisplatin-based chemotherapy in 140 patients with testicular cancer. American Society of Clinical Oncology. 1990; 9: 133.

[42] Pectasides D, Pectasides E, Papaxoinis G, Skondra M, Gerostathou M, Karageorgopoulou S, et al. Testicular function in poor-risk nonseminoma-tous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy. Journal of Andrology. 2009; 30: 280–286.

[43] Jacobsen KD, Theodorsen L, Frssa SD. Spermatogenesis after unilateral orchiectomy for testicular cancer in patients following surveillance policy. Journal of Urology. 2001; 165: 93–96.

[44] Abram McBride J, Lipshultz LI. Male fertility preservation. Current Urology Reports. 2018; 19: 49.

[45] Bujan L, Walschaerts M, Moinard N, Hennebicq S, Saias J, Brugnon F, et al. Impact of chemotherapy and radiotherapy for testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network. Fertility and Sterility. 2013; 100: 673–680. e2.

[46] Kim ED, Lipshultz LI. Evaluation of the infertile male. Impotence and Infertility. 1999; 113: 97–110.

[47] Stahl O, Boyd HA, Giwercman A, Lindholm M, Jensen A, Kruger Kjaer S, et al. Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using danish and swedish national registries. JNCI Journal of the National Cancer Institute. 2011; 103: 398–406.

[48] Blackhall F, DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 7th Edn. Elsevier: Philadelphia. 2005.

[49] Colpi GM, Contalbi GF, Nerva F, Sagone P, Piediferro G. Testicular function following chemo-radiotherapy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2004; 113: S2–S6.

[50] Trottmann M, Becker AJ, Stadler T, Straub J, Soljanik I, Schlenker B, et al. Semen quality in men with malignant diseases before and after therapy and the role of cryopreservation. European Urology. 2007; 52: 355–367.

[51] Ostrowski KA, Walsh TJ. Infertility with testicular cancer. Urologic Clinics of North America. 2015; 42: 409–420.

[52] Clermont Y. Renewal of spermatogonia in man. American Journal of Anatomy. 1966; 118: 509–524.

[53] Pont J, Albrecht W, Postner G, Sellner F, Angel K, Höltl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. Journal of Clinical Oncology. 1996; 14: 441–448.

[54] Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. European Urology. 2010; 58: 134–141.

[55] Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Paternity following treatment for testicular cancer. JNCI: Journal of the National Cancer Institute. 2005; 97: 1580–1588.

[56] Al-Jebari Y. The health of the children in relation to paternal age, cancer, and medication [doctoral thesis]. Lund University. 2021.

[57] Al-Jebari Y, Glimelius I, Berglund Nord C, Cohn-Cedermark G, Ståhl O, Tandstad T, et al. Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: a nationwide register study. PLOS Medicine. 2019; 16: e1002816.

[58] Fraass BA, Kinsella TJ, Harrington FS, Glatstein E. Peripheral dose to the testes: the design and clinical use of a practical and effective gonadal shield. International Journal of Radiation Oncology, Biology, Physics. 1985; 11: 609–615.

[59] Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinology & Metabolism Clinics of North America. 1998; 27: 927–943.

[60] Ståhl O, Eberhard J, Jepson K, Spano M, Cwikiel M, Cavallin-Ståhl E, et al. Sperm DNA integrity in testicular cancer patients. Human Reproduction. 2006; 21: 3199–3205.

[61] Rowley MJ, Leach DR, Warner GA, Heller CG. Effect of graded doses of ionizing radiation on the human testis. Radiation Research. 1974; 59: 665.

[62] Huyghe E, Matsuda T, Daudin M, Chevreau C, Bachaud J, Plante P, et al. Fertility after testicular cancer treatments. Cancer. 2004; 100: 732–737.

[63] Gandini L, Sgrò P, Lombardo F, Paoli D, Culasso F, Toselli L, et al. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Human Reproduction. 2006; 21: 2882–2889.

[64] Qu N, Itoh M, Sakabe K. Effects of chemotherapy and radiotherapy on spermatogenesis: the role of testicular immunology. International Journal of Molecular Sciences. 2019; 20: 957.

[65] Robinson L, Gallos ID, Conner SJ, Rajkhowa M, Miller D, Lewis S, et al. The effect of sperm DNA fragmentation on miscarriage rates: a systematic review and meta-analysis. Human Reproduction. 2012; 27: 2908–2917.

[66] Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage a testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. Journal of Urology. 1993; 149: 237–243.

[67] Masterson TA, Cary C. The use of modified templates in early and advanced stage nonseminomatous germ cell tumor. Advances in Urology. 2018; 2018: 1–5.

[68] Olooto WE. Diagnostic importance of URINALYSIS in endocrinology—a review. Annals of Biological Sciences. 2013; 1: 23–27.

[69] Ghodoussipour S, Daneshmand S. Surgical strategies for postchemother-apy testis cancer. Translational Andrology and Urology. 2020; 9: S74–S82.

[70] Lipshultz LI, Howards SS, Niederberger CS, Lamb D. Infertility in the male. 5th edn. Cambridge University Press: New York. 2022.

[71] Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. Journal of Urology. 1982; 128: 315–320.

[72] Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. Journal of Urology. 2007; 177: 937–943.

[73] Ray B, Hajdu SI, Whitmore WF. Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer. 1974; 33: 340–348.

[74] Janetschek G, Reissigl A, Peschel R, Hobisch A, Bartsch G. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminoma-tous testicular tumor. Urology. 1994; 44: 382–391.

[75] Nelson JB, Chen RN, Bishoff JT, Oh WK, Kantoff PW, Donehower RC, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology. 1999; 54: 1064–1067.

[76] Weissbach L, Boedefeld E, Horstmann-Dubral B. Surgical treatment of stage-I non-seminomatous germ cell testis tumor. European Urology. 1990; 17: 97–106.

[77] Baniel J, Sella A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Seminars in Surgical Oncology. 1999; 17: 263–267.

[78] Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage a testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. Journal of Urology. 1993; 149: 237–243.

[79] Pettus JA, Carver BS, Masterson T, Stasi J, Sheinfeld J. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology. 2009; 73: 328–331.

[80] Matos E, Škrbinc B, Zakotnik B. Fertility in patients treated for testicular cancer. Journal of Cancer Survivorship. 2010; 4: 274–278.

[81] Agarwal A, Ong C, Durairajanayagam D. Contemporary and future insights into fertility preservation in male cancer patients. Translational Andrology and Urology. 2014; 3: 27.

[82] Gilbert K, Nangia AK, Dupree JM, Smith JF, Mehta A. Fertility preservation for men with testicular cancer: is sperm cryopreservation cost effective in the era of assisted reproductive technology? Urologic Oncology: Seminars and Original Investigations. 2018; 36: 92.e1–92.e9.

[83] Hezavehei M, Sharafi M, Kouchesfahani HM, Henkel R, Agarwal A, Esmaeili V, et al. Sperm cryopreservation: a review on current molecular cryobiology and advanced approaches. Reproductive BioMedicine Online. 2018; 37: 327–339.

[84] Agarwal A, Ong C, Durairajanayagam D. Contemporary and future insights into fertility preservation in male cancer patients. Translational Andrology and Urology. 2014; 3: 27–40.

[85] Saito K, Suzuki K, Iwasaki A, Yumura Y, Kubota Y. Sperm cryopreservation before cancer chemotherapy helps in the emotional battle against cancer. Cancer. 2005; 104: 521–524.

[86] Göbel K, Wedell J, Herrmann AM, Wachsmuth L, Pankratz S, Bittner S, et al. 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis. Experimental Neurology. 2013; 248: 62–71.

[87] Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. Journal of Urology. 2019; 202: 272–281.

[88] Moody JA, Ahmed K, Horsfield C, Pedersen MRV, Yap T, Shabbir M. Fertility preservation in testicular cancer—predictors of spermatogenesis. BJU International. 2018; 122: 236–242.

[89] Schrader M, Mller M, Sofikitis N, Straub B, Krause H, Miller K. “Onco-tese”: testicular sperm extraction in azoospermic cancer patients before chemotherapy—new guidelines? Urology. 2003; 61: 421–425.

[90] Isachenko E, Isachenko V, Katkov II, Dessole S, Nawroth F. Vitrification of mammalian spermatozoa in the absence of cryoprotectants: from past practical difficulties to present success. Reproductive BioMedicine Online. 2003; 6: 191–200.

[91] Di Santo M, Tarozzi N, Nadalini M, Borini A. Human sperm cryopreservation: update on techniques, effect on DNA integrity, and implications for ART. Advances in Urology. 2012; 2012: 1–12.

[92] Parks JE, Graham JK. Effects of cryopreservation procedures on sperm membranes. Theriogenology. 1992; 38: 209–222.

[93] Liu J, Tsai YL, Katz E, Compton G, Garcia JE, Baramki TA. Outcome of in-vitro culture of fresh and frozen-thawed human testicular spermatozoa. Human Reproduction. 1997; 12: 1667–1672.

[94] Randrup E, Baum N, Feibus A. Erectile dysfunction and cardiovascular disease. Postgraduate Medicine. 2015; 127: 166–172.

[95] Zhu J, Zhang W, Ou N, Song Y, Kang J, Liang Z, et al. Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis. Translational Andrology and Urology. 2020; 9: 591–600.

[96] Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. Postgraduate Medical Journal. 2017; 93: 679–685.

[97] Becher E. Topical alprostadil cream for the treatment of erectile dysfunction. Expert Opinion on Pharmacotherapy. 2004; 5: 623–632.

[98] Khan MA, Raistrick M, Mikhailidis DP, Morgan RJ. MUSE: clinical experience. Current Medical Research and Opinion. 2002; 18: 64–67.

[99] Ntemou E, Alexandri C, Lybaert P, Goossens E, Demeestere I. Oncofertility: pharmacological protection and immature testicular tissue (ITT)-based strategies for prepubertal and adolescent male cancer patients. International Journal of Molecular Sciences. 2019; 20: 5223.

[100] Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. British Journal of Dermatology. 2019; 181: 350–357.

[101] Hermann B, Sukhwani M, Winkler F, Pascarella J, Peters K, Sheng Y, et

al. Spermatogonial stem cell transplantation into rhesus testes regenerates spermatogenesis producing functional sperm. Cell Stem Cell. 2012; 11: 715–726.

[102] Fayomi AP, Peters K, Sukhwani M, Valli-Pulaski H, Shetty G, Meistrich ML, et al. Autologous grafting of cryopreserved prepubertal rhesus testis produces sperm and offspring. Science. 2019; 363: 1314–1319.

[103] Müller J, Skakkebæk NE. Quantification of germ cells and seminiferous tubules by stereological examination of testicles from 50 boys who suffered from sudden death. International Journal of Andrology. 1983; 6: 143–156.

[104] Mitchell G. The rationale for fractionation in radiotherapy. Clinical Journal of Oncology Nursing. 2013; 17: 412–417.

[105] Hussein AA, Tran ND, Smith JF. Fertility preservation for boys and adolescents facing sterilizing medical therapy. Translational Andrology and Urology. 2014; 3: 382–390.

[106] Allen CM, Lopes F, Mitchell RT, Spears N. How does chemotherapy treatment damage the prepubertal testis? Reproduction. 2018; 156: R209–R233.

[107] Zhang X, Xia Q, Wei R, Song H, Mi J, Lin Z, et al. Melatonin protects spermatogonia from the stress of chemotherapy and oxidation via eliminating reactive oxidative species. Free Radical Biology and Medicine. 2019; 137: 74–86.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.7 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).

Submission Turnaround Time

Conferences

Top